anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To prevent the temp. of the skin from exceeding a definite temp. range and to sufficiently take the lasting time of required temp., by sealing a heat generating composition generating heat in the presence of air in a flat bag body whose single surface is constituted of a specific air permeable film and providing a poultice layer to the other surface thereof. CONSTITUTION:The moisture transmission amount of an air permeable film 5 is 100-400g/m&lt;2&gt;.24hr according to an ASTM method (E-96-80D method) and a heat generating composition consists of 40-75wt.% of an iron powder, 1-10wt.% of activated carbon, 1-10wt.% of sodium chloride, 10-40wt.% of water and 1-40wt.% of a water holding agent, and the filling amount thereof is 500-7000g/m&lt;2&gt;. Herein the water holding agent is composed of at least one substance selected from vermiculite, a silica powder, wood flour and a water absorbable polymer. The filling amount of the poultice base agent in a poultice layer 4 is 400-2500g/m&lt;2&gt;.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a system for preventing forgetfulness and an error, etc. of taking medicine by notifying dosage/use, etc. of medicine and periods/quantity/kinds, etc. of physical exertion/habits, etc. for prevention of diseases/health maintenance by an alarm of a portable terminal, etc.  &lt;P&gt;SOLUTION: The system has a main storage device in which pieces of information, etc. regarding drug prescription/drug history of a patient are accumulated, a device connectable to the portable terminal such as a cellular phone and a PHS/PDA, etc. or a dedicated machine and a data base capable of creating software having functions for issuing the information regarding medicine prescribed based on the drug prescription, etc. of the patient or the physical exertion/habits for prevention of the disease and the health maintenance as an alarm at date/time, etc. when the medicine should be administered/used or the physical exertion/habits should be performed and for displaying the quantity/kinds of the medicine to be administered and content of the exertion/habits to be performed.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
NEW MATERIAL:Hydroxypyrrolidine compounds represented by formula I (Ar is substituted or non-substituted aryl; Z is protecting group for amino group or H; * is optically active carbon). EXAMPLE:2-Methoxyphenylmethyl-4-hydroxy-N-benzyloxycarbonylpyrrolidine. USE:An intermediate for production of an antibiotics anisomycin and derivatives thereof. The antibiotics anisomycin is effective for remedy of diseases due to parthenenogenone protozoa and for protection of damages due to fungi such as powdery mildew of a vegetable, e.g. a bean. PREPARATION:The objective compound of formula I is obtained by directly hydrolyzing the acyloxy group of a new acyloxypyrrolidine compound of formula II (Ar&#39; is substituted or non-substituted aryl) or by protecting the amino group of a new compound of formula II, preparing a new N-substituted pyrrolidine compound of formula III and then hydrolyzing the acyloxy group of thereof.
This study aims to develop and evaluate a deep learning framework that can automatically extract imaging features of the left atrial appendage in patients with atrial fibrillation and combine them with clinical features to predict the risk of ischemic stroke in these patients. The study intends to retrospectively collect clinical data (including patients\&#39; general information, medical history, laboratory tests, etc.) and chest CT images, as well as pulmonary vein CTV images (if available), from patients diagnosed with non-valvular atrial fibrillation between January 2018 and June 2024. The patients will be divided into stroke and non-stroke groups based on whether they have experienced an ischemic stroke, and a data analysis repository will be established. The dataset will be split into training and validation sets. Missing data will be handled, and data labeling will be performed on the pulmonary vein CTV sequence images and virtual non-contrast (VNC) sequence images. The left atrial morphology will be delineated, and a deep learning-based image segmentation network model will be developed to extract and select radiomic features for the prediction system.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a flavor deterioration inhibitor having excellent safety, and giving no affection to the original flavor of food and drink, oral health agents, or the like; namely, a flavor deterioration inhibitor inhibiting flavor deterioration caused mainly by light, heat or oxygen in respective steps of production, distribution and storage.  &lt;P&gt;SOLUTION: This flavor deterioration inhibitor comprises an extract from Syzygium malaccense Merr. et Perry and/or Euphoria longana Steud. seeds. The flavor deterioration inhibitor is added to food and drink, oral health agents or spices to inhibit flavor deterioration caused by light or oxidization.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an effective Aloe vera dried condensed powder.  &lt;P&gt;SOLUTION: When drying, condensing and powdering the Aloe vera, low temperature and moisture-keeping treatment drying is performed to keep characteristic slimy feeling and components of the Aloe vera. Thereby, the slimy feeling and components of the Aloe vera can be enclosed in the powder. By the treatment, the dried, condensed and powdered Aloe vera has a state like the raw Aloe vera and recovers the slimy feeling and the components of the Aloe vera by adding water. The Aloe vera gel has effective components good for the body and beauty, but the conventional Aloe vera dried condensed powder has no slimy feeling and almost no effectiveness. Thereby, use feeling and effects of original Aloe vera gel have not been conventionally not felt, but are improved by the low temperature moisture-keeping treatment drying.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
FIELD: veterinary pharmacology, obstetrics, gynecology. SUBSTANCE: for treating cows at retained afterbirth one should prepare a solution consisted of 33% tincture of sunflower seed- containing calathide supplemented with the salts of macro- and microelements at the rate of 100 ml: potassium iodine 0.8-1.2 mg, copper sulfate 45-55 mg, manganese sulfate 1.5-2.5 mg, zinc sulfate 25-35 mg, cobalt chloride 1.2-1.4 mg, sodium selenite 0.3-0.5 mg, sodium chromide 0.65- 0.75 mg, potassium bromide 0.6-0.8 mg. Preparation is injected into jugular vein at the dosage of 2.5-3.5 ml. Results obtained demonstrate that intravenous injection of phytopreparation at its nominal name of ERA-&#34;h&#34; promotes afterbirth detachment in all the cows during 2-3 h. Injection of the suggested phytopreparation for cows in case of retained afterbirth prevents complications and leads to better recovery in animals. EFFECT: higher efficiency of treatment. 1 tbl
PURPOSE:To improve the compressing efficiency of the entire picture by dividing one picture data into &gt;=2pts and compressing the split picture data with different compressing rates in response to the required amount of picture information for each part. CONSTITUTION:The picture data of an original picture 1 is split into &gt;=2pts. In this case, the original picture 1 includes a part A requiring detailed information and a part B whose outline is understood and the data is split into the part A 5a and the part B 5b. Then the picture data of the parts 5a, 5b is compressed with different compressing rates in response to the required amount of picture information with respect to each part. That is, the part A 5a is compressed into a compression rate of 1/n and the part B 5b is compressed with a compression rate of 1/m. Thus, the compressed picture 3 compressing the entire picture data of the original picture 1 is obtained.
PURPOSE:To obtain a tacky sheet preferably usable for spreading plaster, by laminating a tacky agent comprising a diene copolymer to a substrate sheet consisting of a vinyl chloride polymer and an ethylene-vinyl acetate copolymer and bonding. CONSTITUTION:100pts.wt. vinyl chloride polymer having excellent feeling and flexibility is blended with 10-100pts.wt. ethylene-vinyl acetate copolymer having 5-85wt.% vinyl acetate content and 10-100pts.wt. ester-based high-molecular weight plasticizer having &gt;=800, preferably &gt;=1,000 average molecular weight to give a resin composition. A layer of styrene-diene block copolymer as a tacky agent is directly laminated and bonded to a substrate layer consisting of the resin composition to give a tacky sheet.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a clinical trial data management method and clinical trial data management system capable of obtaining a precise case report quickly by reducing time and labor as far as possible.  &lt;P&gt;SOLUTION: An information processor is connected to a pharmaceutical company, hospital, and a clinical trial data management center via a network. In the information processor, a person who owns an access right and its access content are different depending on the pharmaceutical company, the hospital, and the clinical trial data management center. A medical doctor at the hospital inputs clinical trial data to a picture created by the clinical trial data management center in the information processor connected to the network. The pharmaceutical company looks at the clinical trial data in the picture created by the clinical trial data management center and can comment on (or enquire about) the clinical trial data. The medical doctor looks at the comment, corrects the clinical trial data if necessary, and describes his or her reason for the correction. The pharmaceutical company fixes the clinical trial data returned from the hospital and outputs the data on the clinical trial.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The present invention belongs to a Chinese patent medicine for treating bone retrograde affection. Through clinical research for years, the pathogenic mechanisms of bone retrograde affection are held, and the clinical manifestation belongs to small joint disease or named as small joint functional disorder. The theory of the treatment of both symptoms and root causes of diseases of traditional Chinese medicine is adopted, and the present invention takes effects on &#39;evil repletion positive weakness&#39;. The formula of the present invention has the functions of activating blood circulation to dissipate blood stasis, expelling wind, eliminating cold, regulating qi-flowing for relieving pain, invigorating the kidney, strengthening the bones for generating pith and inhibiting hyperosteogeny. The formula comprises cholera of sheep, rhizoma cibotii, prepared rhizome of rehmannia, rhizoma drynariae, cistanche salsa, suberect spatholobus, safflower, corydalis tuber and sugar or honey as assistance. The effective rate of the present invention is 95.4%, and the cure rate is 87.2%. Common symptoms can be cured for 20 days, serious symptoms can be obviously lightened, and the present invention can prevent the states of illness from relapsing.
Compounds of the formula I are prepared by reaction of a compound of the formula V with the compound of the formula VI. The meaning of the substituents A and A&lt;1&gt; can be taken from Claim 1. The compounds prepared can be used as active compounds in pharmaceutical preparations having antibacterial action. They are used e.g. for the control of Shig. dysenteriae, Sal. enteritidis, Haemophilus and Neisseria infections. &lt;IMAGE&gt;
An activity monitoring system measures the effectiveness of pain management using using data from motion or activity sensors attached to the patient&#39;s body to compute measures of exertion level of a patient. Increased levels of exertion are an indication of successful pain management. The patient&#39;s walking gait smoothness and walking gait stability are also graded as indicators of pain management effectiveness. The motion or activity sensors may be part of a temporary stimulation system used during percutaneous trials, part of a permanent implanted system, or an independent sensor package carried on the patient&#39;s body. The particular location and axes of the motion or activity sensors may be chosen based on the location of the pain being treated. The effectiveness of a particular pain management stimulation parameter set is based on the statistics accumulated over a period of time, for example one hour.
NEW MATERIAL:The benzothiazole derivative of formula I (R&lt;1&gt; and R&lt;2&gt; are H, lower alkyl, haloalkyl, or hydroxyalkyl; R&lt;1&gt; and R&lt;2&gt; may together with adjacent N atom form a 5-6-membered saturated heterocyclic group which may contain additional O or N atom; when said heterocyclic group is piperazine ring, it may have a substituent group such as alkyl, alkenyl, phenyl, etc. at the 4-position) and its salt. EXAMPLE:6-(1-Piperazinylcarbonyl)-2-benzothiazolone. USE:A cardiotonic agent and hypotensor. It increases the contraction of the cardiac muscle and the coronary blood flow rate, etc. PREPARATION:The compound of formula I can be produced e.g. by reacting the benzothiazole derivative of formula II with the amine of formula III or its amino-activated derivative.
PCT No. PCT/JP94/01487 Sec. 371 Date May 10, 1995 Sec. 102(e) Date May 10, 1995 PCT Filed Sep. 8, 1994 PCT Pub. No. WO95/07276 PCT Pub. Date Mar. 16, 1995Novel heterobicyclic sulfonamide and sulfonic ester derivatives represented by the following general formula(I), which exhibit an antitumor activity and are lowly toxic, and processes for the preparation thereof. A sulfonamide derivative and a sulfonic ester derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof:    &lt;IMAGE&gt;  (I)  wherein A represents a monocyclic or bicyclic aromatic ring which may be substituted; B represents a six-membered unsaturated hydrocarbon ring or a six-membered unsaturated heterocycle containing one nitrogen atom, each of which may be substituted; C represents a five-membered heterocycle containing one or two nitrogen atoms which may be substituted; W represents a single bond or a group represented by formula -CH=CH-; X represents a group represented by formula -N(R1)- or oxygen; Y represents carbon or nitrogen; Z represents a group represented by formula -N(R2)- or nitrogen; and R1 and R2 may be the same or different from each other and each represent hydrogen or lower alkyl.
PURPOSE:To obtain the transparent air bubble-dispersed jelly hair cosmetic good in the stability of the air bubbles with time, beautiful in appearance, having the functions of conventional hair cosmetics, and charged in a transparent resin container. CONSTITUTION:The transparent jelly hair cosmetic contains (A) a water-soluble polymeric compound, e.g. polyvinyl alcohol or a carboxyvinyl polymer, and (B) a polyhydric alcohol, e.g. propylene glycol or glycerol as essential components, and further contains air bubbles. The cosmetic is charged in a transparent resin container having an oxygen permeability of 11-2700cc/m&lt;2&gt;, 24hrs, atm, regulated by JIS Z 1707 (20 deg.C, relative humidity of 65%). The component (A) comprises usually the combination of two kinds of the compounds and is preferably compounded in an amount of 0.1-7wt.%. The compounding amount of the component (B) is preferably 0.5-50wt.%. The material for the transparent container includes low density polyethylene, high density polyethylene, polypropylene, polystyrene, high impact-resistant polystyrene, and a tubular container whose body part comprises low density polyethylene is especially preferable.
A computer system synthesizes multiple streams of raw blood coagulation function data into a single display or instrument, showing a synthetic model of a blood clot, which is generated according to algorithms and rendered dynamically in real time by a graphics processor. A computer-implemented method, according to an embodiment, creates a dynamic rendering of a synthetic blood clot model (101), representing the condition of the actual monitored patient&#39;s blood coagulation system according to the raw input data. The method uses alterations in the states or attributes of specified parts of a displayed blood clot. The dynamic alterations involve, but are not limited to, the shape of parts, changes in the volume of parts, in a three-dimensional representation, or the area of parts, in a two-dimensional representation, number and movement of parts, and changes in the color of parts. The blood clot may be looked at from all angles according to user input. The dynamically altered parts of the visual clot model, according to an embodiment include background (1), drug indicator (2), fibrin mesh indicator (3), plasmatic coagulation factor indicator (4), blood drops and pool of blood indicator (5), and platelet indicator (6).
A composition for use in the internal examination of animals particularly humans either living or dead comprises at least one fluorescent compound which absorbs ultra-violet radiation in the range of from 3000 to 3800 Angstroms, re-emits in the range of from 4000 to 5500 Angstroms and contains a carbon-carbon double bond adjacent to at least one aryl group, said aryl group containing, as substituents, one or more carboxylic acid or sulphonic acid groups, or a salt of such a compound, together with a carrier or diluent. The salt may be an alkali metal or ammonium salt or a salt formed from the group \sLN, R1, R2, R3, R4, wherein R1 is alkyl, aryl, hydroxyalkyl or hydroxyaryl and R2, R3 and R4 represent hydrogen or any of the groups representable by R1.  The fluorescent compound may be a compound of formula &lt;FORM:0968410/C4-C5/1&gt; wherein R5 is an organic group attached to the nitrogen via a carbon atom, e.g. -COR10, wherein R10 represents an aryl group or &lt;FORM:0968410/C4-C5/2&gt; in which R6, R7, R8 and R9 represents hydrogen or organic groups.  For administration to living animals, 1 to 13% of the fluorescent compound in a parenteral solvent such as water.  The compositions may also be used as aqueous solutions buffered at pH 7.0.  Other carriers are polyvinyl acetate, diethylene glycol and monoethanolamine. They may be administered in the form of cakes, pastilles, tablets, pills, capsules, dragees and other oral preparations; rectal preparations and parental preparations. They may be introduced into the hollow organs and excretory and secretory passages.  The examination of the fluorescence produced by the compositions of the invention can be carried out visually, microscopically, photographically or photometrically.  Specific examples, in general, are of stilbene derivatives, e.g. 2,21-disulphonic - 4,41 - bis(2,4 - di - anilino, 1,3,5 - triazinyl, 6-amino)stilbene.
PURPOSE:To obtain a carcinostatic agent having low toxicity and sustained and high antitumor action, containing a derivative of betulin, plant derived pentacyclic compound as an active ingredient. CONSTITUTION:A carcinostatic agent containing a compound shown by the formula (R1 and R2 are hydroxyl, &lt;=18C acyl or p-toluenesulfonyloxy but are not simultaneously hydroxyl; R3 is methyl or halo-methyl) as an active ingredient. The compound shown by the formula can be orally or parenterally administered to mammals including human. The parenteral administration is carried out intravenously, through the abdominal cavity or hypodermically. A dose of the carcinostatic agent is 10mg-100mg/time calculated as the active ingredient and administered approximately daily or about 30g/time is preferably administered every 3-7 days. 3,28-Di-acetoxylup-20(29)-ene, etc., may be cited as the compound shown by the formula.
PURPOSE:To obtain the microcapsule of cosmetics having excellent light resistance, safety, adhesiveness, etc., by including coloring matter, UV absorber and/or antioxidant into spherical fine particles essentially consisting of silica and having specific average grain sizes. CONSTITUTION:The coloring matters are dissolved in an aq. silicate soln. of an alkali metal or the coloring matters treated with a water-soluble high polymer are dispersed therein. Further, the UV absorber and/or antioxidant which is soluble in an aq. alkaline sol. and insoluble in an aq. neutral or acidic soln. and an org. solvent is added and dissolved therein. This aq. soln., the org. solvent of &lt;=5% solubility in water, the coloring matters, the UV absorber and/or antioxidant are mixed to prepare an emulsion. The acidic aq. soln. which forms a water-insoluble precipitate by the neutralization reaction with the alkali metal silicate and the UV absorber and/or antioxidant is mixed with the above-mentioned emulsion. The mixture is filtered, rinsed and dried, by which the light resistant microcapsule constituted by including the coloring matters and the UV absorber and/or antioxidant into the spherical fine particles essentially consisting of the silica and having 0.1 to 30mum grain sizes is obtd.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a composition having an antiaging function, to prepare a cosmetic containing the same, and to provide food and drink containing the same.  &lt;P&gt;SOLUTION: The antiaging composition contains an extract of unpolished rice fermented by Aspergillus oryzae or an extract of polished rice fermented by the Aspergillus oryzae as an essential component. The composition may further contain an extract of Mallotus philippinensis. The composition may furthermore contain an extract of a plant selected from Aloe vera, Momordica grosvenorii, Eucommia ulmoides, Lepidiummee yenii, Avena sativa, Gentianella alborocea, Hibiscus sabdariffa, Anethum graveolens, Calendula officinalis, Euphoria longana, Foeniculum vulgare, Thea sinensis, Mentha pulegium, Urtrica thunbergiana, Areca catechu, Fagopyrum tartaricum, Uncaria gambir, and Terminalia arjuna of a combretaceous plant. The cosmetic and the food and drink contain the antiaging composition, respectively.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
Compounds of general formula (I), wherein R¿1? and R¿2?, which are the same or different, are a hydrogen atom or a saturated or unsaturated hydrocarbon radical having up to 24 carbon atoms and being optionally interrupted by one or more heteroatoms and provided with one or more functional groupings; or R¿1? and R¿2?, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring optionally containing one or more heteroatoms selected from nitrogen, oxygen and sulphur; or R¿1? and R¿2?, taken together, form a radical (a), wherein R&#39;¿1? and R&#39;¿2?, which are the same or different, are a hydrogen atom or a saturated or unsaturated hydrocarbon radical having up to 23 carbon atoms and being optionally interrupted by one or more heteroatoms and provided with one or more functional groupings, and Z is a hydrogen atom or a carboxylic acid residue having up to 18 carbon atoms; as well as acid addition salts thereof. The compounds of formula (I) have valuable antibiotic properties.